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Croatia needs a registry of 
patients undergoing direct 
current cardioversion for 
persistent atrial fibrillation/
flutter
To the editor:
Direct current cardioversion (DCC) is a procedure used to 
restore sinus rhythm in patients with persistent atrial fibril-
lation (AF) or atrial flutter (AFL) (1). It is associated with a 
1%-2% risk of thromboembolic events (2). In patients with 
persistent AF/AFL lasting longer than 48 hours, this risk can 
be reduced by adequate anticoagulation or exclusion of 
atrial thrombi using transesophageal echocardiography 
(TEE). Guidelines for the management of atrial fibrillation of 
the European Society of Cardiology (ESC) (2) suggest two 
approaches: a) prophylactic anticoagulation over at least 
3 weeks before and 4 weeks after the procedure, implying 
that the international normalized ratio (INR) is between 2.0 
and 3.0 if vitamin K antagonists (VKA) are used, or by us-
ing direct orally active anticoagulants (DOACs) (2-5); b) TEE 
with anticoagulation therapy immediately before (low mo-
lecular weight heparins with VKA) and over 4 weeks after 
the procedure (VKA with INR 2.0-3.0, or DOACs) (2).
The aim of this study was to retrospectively assess compli-
ance of the management of patients with persistent AF/
AFL lasting longer than 48 hours at one university hospi-
tal (UH) and one general hospital (GH), considered repre-
sentative of tertiary and secondary health care providers 
in Croatia, with the ESC guidelines. We identified all pa-
tients undergoing the procedure between September 3, 
2010 and September 3, 2014 at UH and between March 1, 
2009 and July 7, 2014 at GH. Patients were identified and 
confirmed through the hospital electronic databases and 
hardcopy archives.
339 patients (age 20 to 92 years, median 65, interquartile 
range 58-71; 67.9% men; 41.6% suffering the first AF/
AFL episode), 284 at UH and 55 at GH, were initially con-
sidered for the procedure, but some were eventually 
dropped mainly due to spontaneous cardioversion to 
sinus rhythm (Figure 1). Considering those who entered 
the procedure, two main observations were made: a) at 
GH, the approach was compliant with the ESC guideline 
option based on prophylactic anticoagulation (over at 
least 3 weeks before DCC) for all, whereas at UH the ap-
proach was a combination of such an approach and the 
one based on the use of TEE (Figure 1); b) all records were 
strikingly sparse. For example, VKA were used for antico-
agulation in the vast majority of the patients (97.8% at 
UH, 72.7% at GH), but no INR values were available for 
estimation of the time in therapeutic range (TTR) before 
DCC, and INR values on the day of DCC were missing for 
21.1% patients at UH and 25.0% patients at GH (Figure 
1). Moreover, no trace of a “structured” post-DCC monitor-
ing/follow-up was found.
Considering those anticoagulated with VKA (n = 261 at UH, 
n = 32 at GH) (Figure 1), on the day of the planned DCC, the 
explicit evidence of an INR within the target range could 
be ascertained for only 32.6% patients at UH and 43.8% at 
GH (Figure 1), whereas INR was too low in 35.6% and 28.1% 
of the patients, respectively, and too high in 10.7% and 
3.1% of the patients, respectively (Figure 1). The planned 
DCC was postponed for various reasons in 22.1% patients 
at UH and in 27.3% patients at GH (Figure 1). Considering 
those who actually underwent DCC and were anticoagu-
lated by VKA (n = 204 at UH, n = 24 at GH), the explicit evi-
dence of an INR within the target range at DCC was found 
for only 32.4% of the patients at UH and for 58.3% at GH, 
whereas INR was too low in 35.8% and 16.7% of the pa-
tients, respectively, and too high in 12.8% and 4.2% of the 
patients, respectively – no data were available for the 
remaining patients (Figure 1). DCC was successful in 
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90.4% patients at UH and in 69.0% at GH (Figure 1), but 
no records on possible complications (or explicit records 
of a lack of complications) could be identified for 97.6% 
patients at UH and 93.8% patients at GH (Figure 1). Yet, de-
spite the lack of any trace of a safety follow-up, 2 (1.0%) 
patients treated at UH were hospitalized at UH within the 
subsequent 14 days due to a stroke (no cases at GH), and 
1.4% at UH and 6.2% at GH experienced bleedings (Figure 
1). Moreover, 2 more patients at UH experienced a stroke, 
but DCC was actually postponed due to a thrombus in the 
left atrium visible by TEE. One of them had INR<2.0 (on the 
day of the planned DCC), and for the other, the INR value 
was unknown.
In patients with AF/AFL, thromboprophylaxis is an essen-
tial treatment as it greatly reduces the risk of stroke, and if 
VKA are used for the purpose, they largely fail to achieve 
the therapeutic objective if time with INR in the therapeu-
tic range is below 60% (6-8). DCC further increases the risk 
of thromboembolic events, hence thromboprophylaxis is 
a standard preparatory procedure (2). Since DCC is not a 
very common procedure, evidence about efficacy/safety 
of thromboprophylactic treatments comes mostly from 
subgroup analyses in large clinical trials or from observa-
tional studies (5). Under such circumstances, systematic 
follow-up of patients in daily practice, eg, through regis-
tries/structured databases at the institutional or national 
levels (9,10) could provide sound grounds for efficacy and 
safety assessment, identification of modifying factors and, 
if needed, adjustment of practice. The present data clearly 
demonstrate that such a re-appraisal in the two observed 
institutions – which set the indication for DCC, determine 
the overall protocol, and execute it – would be impossi-
ble due to extremely sparse documentation inappropriate 
for any reliable assessment. Moreover, the available data 
strongly suggest that the thromboprophylactic practice 
Figure 1. Flow diagram of patients considered for direct current cardioversion (DCC) due to atrial fibrillation/atrial flutter identified 
in the present study at two hospitals (one university hospital, one general hospital) in Croatia, between 2009 and 2014. The steps of 
the procedures are indicated by the arrows. DOAC – direct orally active anticoagulant; INR – international normalized ratio; LA – left 
atrium; TEE – transesophageal echocardiography; TTR – time in therapeutic range; VKA – vitamin K antagonists.
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and follow-up is poor. Overall, the present work empha-
sizes a need for establishment of a registry of patients with 
AF/AFL undergoing DCC at the national level.
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